Company intelligence / Profile preview

EpiCor

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

EpiCor is a clinically validated postbiotic ingredient derived from the fermentation of Saccharomyces cerevisiae. It has been the subject of more than 15 published studies demonstrating its ability to support immune and digestive health by modulating the gut microbiome. The product is widely used as an ingredient in dietary supplements and functional foods globally

Therapeutic areas: GastroenterologyImmunology
Modalities: Postbiotic ingredient (whole food fermentate derived from Saccharomyces cerevisiae fermentation)
Industry: Food & Nutrition

Partnerships

Formulated into products by numerous global supplement brandsdistributed via Cargill’s network

Beyond the preview

Go deeper on EpiCor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiCor.

Explore the full profile